Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GLUE Monte Rosa Therapeutics

Market Closed 11-22 16:00:00 EST

8.49

+0.14

+1.68%

盘后8.49

+0.000.00%

19:32 EST

High8.67	Low8.24	Vol369.98K
Open8.36	D1 Closing8.35	Amplitude5.15%
Mkt Cap521.59M	Tradable Cap313.74M	Total Shares61.44M
T/O3.15M	T/O Rate1.00%	Tradable Shares36.95M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"GLUE","market":"US","secType":"STK","nameCN":"Monte Rosa Therapeutics","latestPrice":8.49,"timestamp":1732309200000,"preClose":8.35,"halted":0,"volume":369980,"hourTrading":{"tag":"盘后","latestPrice":8.49,"preClose":8.49,"latestTime":"19:32 EST","volume":6745,"amount":57265.54,"timestamp":1732321963254},"delay":0,"floatShares":36954081,"shares":61436116,"eps":-1.765395,"marketStatus":"Market Closed","change":0.14,"latestTime":"11-22 16:00:00 EST","open":8.36,"high":8.67,"low":8.24,"amount":3150439.26678,"amplitude":0.051497,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.765395,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732525200000},"marketStatusCode":7,"adr":0,"listingDate":1624507200000,"exchange":"NASDAQ","adjPreClose":8.35,"preHourTrading":{"tag":"盘前","latestPrice":8.35,"preClose":8.35,"latestTime":"08:45 EST","volume":104,"amount":867.36,"timestamp":1732283116846},"postHourTrading":{"tag":"盘后","latestPrice":8.49,"preClose":8.49,"latestTime":"19:32 EST","volume":6745,"amount":57265.54,"timestamp":1732321963254},"volumeRatio":0.3688396951394924,"impliedVol":0.9259,"impliedVolPercentile":0.1587},"requestUrl":"/m/hq/s/GLUE","defaultTab":"news","newsList":[{"id":"2483330452","title":"Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 100.47%: Read This Before Placing a Bet","url":"https://stock-news.laohu8.com/highlight/detail?id=2483330452","media":"Zacks","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483330452?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:55","pubTimestamp":1731682510,"startTime":"0","endTime":"0","summary":"Shares of Monte Rosa Therapeutics  have gained 54.5% over the past four weeks to close the last trading session at $8.48, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $17 indicates a potential upside of 100.5%.The average comprises six short-term price targets ranging from a low of $15 to a high of $20, with a standard deviation of $2.45. While the lowest estimate indicates an increase of 76.9% from the current price level, the most optimistic estimate points to a 135.9% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing RO","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/UPInF06X6fJkTqeimnpZuQ--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/UPInF06X6fJkTqeimnpZuQ--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-think-monte-145510726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLUE","BK4139","BK4539"],"gpt_icon":0},{"id":"2483361009","title":"Monte Rosa Therapeutics to Participate in the Jefferies London Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2483361009","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483361009?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:00","pubTimestamp":1731499200,"startTime":"0","endTime":"0","summary":"BOSTON, Nov.  13, 2024  (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/13/2980098/0/en/Monte-Rosa-Therapeutics-to-Participate-in-the-Jefferies-London-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4137","BK4139","GLUE","BK4539","HCSG"],"gpt_icon":0},{"id":"2482787064","title":"Owning 47% shares,institutional owners seem interested in Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE),","url":"https://stock-news.laohu8.com/highlight/detail?id=2482787064","media":"Simply Wall St.","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482787064?lang=en_us&edition=fundamental","pubTime":"2024-11-11 20:45","pubTimestamp":1731329138,"startTime":"0","endTime":"0","summary":"Given the large stake in the stock by institutions, Monte Rosa Therapeutics' stock price might be vulnerable to their trading decisions. A total of 6 investors have a majority stake in the company with 55% ownership. Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company. To get a sense of who is truly in control of Monte Rosa Therapeutics, Inc. , it is important to understand the ownership structure of the business. With 47% stake, institutions possess the maximum shares in the company. Put another way, the group faces the maximum upside potential .Because institutional owners have a huge pool of resources and liquidity, their investing decisions tend to carry a great deal of weight, especially with individual investors. Therefore, a good portion of institutional money invested in the company is usually a huge vote of confidence on its future.Check out our latest analysis for Monte Rosa Therapeutics. NasdaqGS:GLUE Earn","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/d3vISzLZXw94x30FKv9beA--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4d522452d0da08d8412701a84270533b"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/owning-47-shares-institutional-owners-124538176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLUE","BK4112","NDAQ","NQmain","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2095319765.USD","MNQmain","TQQQ","IE00BGHQF748.EUR","BK4539","QLD","BK4139","IE00B3QW5Z07.USD","BK4585",".IXIC","QID","PSQ","BK4588","SQQQ","LU2210150020.SGD","LU2210149790.SGD"],"gpt_icon":1},{"id":"2481148077","title":"U.S. RESEARCH ROUNDUP-Bath & Body Works, Datadog, Savers value Village","url":"https://stock-news.laohu8.com/highlight/detail?id=2481148077","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481148077?lang=en_us&edition=fundamental","pubTime":"2024-11-08 15:30","pubTimestamp":1731051041,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Bath & Body Works, Datadog, Savers value VillageNov 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, includ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241108:nL4N3MF0VN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRC","XRAY","MTSI","SG9999011175.SGD","BK4198","ACLX","EPAM","INGN","AFRM","LU0456854461.SGD","NET","MNST","ANET","PODD","HAL","LU1548497426.USD","FTNT","COTY","SGXZ51526630.SGD","EMR","FLYW","DDOG","BK4110","HST","LU0053671581.USD","CPAY","FHN","EVH","IE0008368304.USD","MEG","CTVA","BILL","BBWI","CARS","IE00B19Z9Z06.USD","MNMD","ACRE","BRDG","HAIN","FIVN","LU0757428866.USD","APD","ASLE","LYFT","ACVA","SVV","ABNB","GLUE","BSY","BK4535"],"gpt_icon":1},{"id":"2481123182","title":"Monte Rosa Therapeutics (GLUE) Reports Q3 Loss, Tops Revenue Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2481123182","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481123182?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:35","pubTimestamp":1730986506,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics  came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.70 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 35.56%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.50 per share when it actually produced a loss of $0.43, delivering a surprise of 14%.Monte Rosa Therapeutics , which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $9.22 million for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 103.13%. This compares to zero revenues a year ago.Monte Rosa Therapeutics shares have added about 67.3% since the beginning of the year versus the S&P 500's gain of 24.3%.While Monte Rosa Therapeutics has outperformed the market so far this year, the question that comes to investors' minds is: what's next for t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/monte-rosa-therapeutics-glue-reports-133506362.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLUE"],"gpt_icon":0},{"id":"2481095906","title":"Monte Rosa Therapeutics reports Q3 EPS (29c), consensus (49c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2481095906","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481095906?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:38","pubTimestamp":1730983118,"startTime":"0","endTime":"0","summary":"Reports Q3 revenue $9.216M, consensus $2.62M. “We continue to make significant progress towards pioneering the discovery and development of highly ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-reports-q3-eps-29c-consensus-49c?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/monte-rosa-therapeutics-reports-q3-eps-29c-consensus-49c?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GLUE"],"gpt_icon":0},{"id":"2481909616","title":"Monte Rosa Therapeutics: Q3 Earnings Snapshot","url":"https://stock-news.laohu8.com/highlight/detail?id=2481909616","media":"Associated Press Finance","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481909616?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:30","pubTimestamp":1730982614,"startTime":"0","endTime":"0","summary":"BOSTON  — BOSTON  — Monte Rosa Therapeutics Inc.  on Thursday reported a loss of $23.9 million in its third quarter.The Boston-based company said it had a loss of 29 cents per share.The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 45 cents per share.The biopharmaceutical company posted revenue of $9.2 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $4.5 million.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/monte-rosa-therapeutics-q3-earnings-123014078.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GLUE"],"gpt_icon":0},{"id":"2481490890","title":"BRIEF-Monte Rosa Therapeutics Q3 Pretax Profit USD -23.788 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481490890","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481490890?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980850,"startTime":"0","endTime":"0","summary":"Nov 07 (Reuters) - Monte Rosa Therapeutics Q3 net income USD -23.859 million. * Q3 operating expenses USD 35.743 million * Q3 operating income USD -26.527 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GLUE","USD","BK4139","BK4539"],"gpt_icon":0},{"id":"2481997042","title":"Monte Rosa Therapeutics Q3 Operating Income USD -26.527 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2481997042","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481997042?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980805,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nPLX9F27C6:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GLUE","BK4139","BK4539"],"gpt_icon":0},{"id":"2481590363","title":"Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2481590363","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481590363?lang=en_us&edition=fundamental","pubTime":"2024-11-07 20:00","pubTimestamp":1730980800,"startTime":"0","endTime":"0","summary":"Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed molecular glue degraders including MRT-6160 for immune-related conditions; $150M upfront payment, eligible for up to $2.1B milestones and U.S. P&L share. MRT-6160 Phase 1 SAD/MAD study ongoing with initial clinical data expected by Q1 2025. Phase 1/2 study of MRT-2359, in development for MYC-driven solid tumors, ongoing with updated clinical results anticipated by year-end. MRT-8102, a NEK7-directed molecular glue degrader targeting diseases driven by IL-1β and the NLRP3 inflammasome, on track for IND filing in H1 2025. Dr. Warmuth continued, “We have made significant progress advancing our second I&I program, MRT-8102, toward an expected IND application in the first half of 2025. Turning towards our oncology pipeline, we look forward to sharing updated clinical results from the Phase 1 dose escalation portion of the MRT-2359 study by year-end, and we’re pleased with the","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1hBAE5qiNVdDUIOCnfQ6sA--~B/aD0xMTQyO3c9NDE2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/a8578031236fef7f415e1357262f9cf4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1hBAE5qiNVdDUIOCnfQ6sA--~B/aD0xMTQyO3c9NDE2NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/a8578031236fef7f415e1357262f9cf4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/monte-rosa-therapeutics-announces-third-120000117.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","GLUE","BK4139"],"gpt_icon":0},{"id":"2481932803","title":"Are You Looking for a Top Momentum Pick? Why Monte Rosa Therapeutics (GLUE) is a Great Choice","url":"https://stock-news.laohu8.com/highlight/detail?id=2481932803","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481932803?lang=en_us&edition=fundamental","pubTime":"2024-11-07 01:00","pubTimestamp":1730912413,"startTime":"0","endTime":"0","summary":"Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be \"buying high, but hoping to sell even higher.\" With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us.","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7h8ntzJXcDOdVmDKQ08gRg--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/e8e4b0344809eaac6d73c9fd25fd180a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/looking-top-momentum-pick-why-170013359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4142","BK4539","GLUE","CHH","BK4139"],"gpt_icon":0},{"id":"2479278022","title":"Wall Street Analysts Believe Monte Rosa Therapeutics (GLUE) Could Rally 67.24%: Here's is How to Trade","url":"https://stock-news.laohu8.com/highlight/detail?id=2479278022","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479278022?lang=en_us&edition=fundamental","pubTime":"2024-10-30 21:55","pubTimestamp":1730296504,"startTime":"0","endTime":"0","summary":"Shares of Monte Rosa Therapeutics  have gained 76.8% over the past four weeks to close the last trading session at $9.37, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $15.67 indicates a potential upside of 67.2%.The average comprises six short-term price targets ranging from a low of $7 to a high of $20, with a standard deviation of $4.80. While the lowest estimate indicates a decline of 25.3% from the current price level, the most optimistic estimate points to an 113.5% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts.That said, while investors should not entirely ignore price targets, making an investment decision solely based on them could lead to disappointing ROI. So, p","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6Ex_CnpNXcMseRWMhPXBow--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6Ex_CnpNXcMseRWMhPXBow--~B/aD01ODg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/3496571a811465d910e99bd171c71a94"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/wall-street-analysts-believe-monte-135504403.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4539","BK4139","GLUE"],"gpt_icon":0},{"id":"2479428212","title":"Monte Rosa Therapeutics Shares Skyrocket After $2.1 Billion Deal with Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2479428212","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479428212?lang=en_us&edition=fundamental","pubTime":"2024-10-29 22:57","pubTimestamp":1730213832,"startTime":"0","endTime":"0","summary":"In a recent move in the Biotech industry, Monte Rosa Therapeutics  got into a great partnership with Swiss Novartis for up to $2.1 billion, lifting shares sky-high. The document deals with both parties' efforts to MRT-6160, a drug to treat ailments related to the immune system that is presently under phase I clinical trials.GuruFocus has detected 4 Warning Signs with GLUE.As part of the deal, Novartis is set to transfer $150 million to Monte Rosa to buy a worldwide license for MRT-6160 and other potential molecular glue degrader treatments. Beyond the $25 million upfront fee, Monte Rosa might be able to get additional payments for development, regulatory, and commercialization milestones, adding up to $2.1 billion every time the development enters Phase 2 studies. Royal has also included tiered royalties on the products to be sold in markets outside the United States of America.Novartis will take over clinical development and later commercialization starting in Phase 2, while Monte Ros","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Fku.9wELr8JsloL3BHBTLw--~B/aD0yODU7dz00MjE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/de028088c2fb810b95745f672ea59104","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Fku.9wELr8JsloL3BHBTLw--~B/aD0yODU7dz00MjE7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/de028088c2fb810b95745f672ea59104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/monte-rosa-therapeutics-shares-skyrocket-145712888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NVS","BK4539","BK4139","GLUE"],"gpt_icon":0},{"id":"1159042407","title":"Stock Track | Monte Rosa Soars Over 140% on $2.25 Billion Novartis Licensing Deal for Novel Immune Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1159042407","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159042407?lang=en_us&edition=fundamental","pubTime":"2024-10-29 16:02","pubTimestamp":1730188938,"startTime":"0","endTime":"0","summary":"Shares of Monte Rosa Therapeutics  skyrocketed over 140% in pre-market trading on October 29th, driven by a massive $2.25 billion global licensing agreement with pharmaceutical giant Novartis.Under the deal terms, Novartis gains exclusive worldwide rights to develop and commercialize Monte Rosa's lead drug program MRT-6160, an oral degrader of the VAV1 protein that regulates immune cell signaling. Novartis paid $150 million upfront and could pay up to $2.1 billion more in development, regulatory","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GLUE"],"gpt_icon":0},{"id":"1117889621","title":"Stock Track | Monte Rosa Soars on $2.25 Billion Novartis Deal for Novel Immune Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1117889621","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117889621?lang=en_us&edition=fundamental","pubTime":"2024-10-29 08:33","pubTimestamp":1730161983,"startTime":"0","endTime":"0","summary":"Shares of $Monte Rosa Therapeutics$, Inc.  skyrocketed 142% on October 28, 2024 after the clinical-stage biotech announced a massive $2.25 billion global licensing agreement with pharmaceutical giant Novartis. The deal gives Novartis exclusive worldwide rights to develop and commercialize Monte Rosa's lead program MRT-6160 and other VAV1-directed molecular glue degrader candidates for immune-mediated diseases.Under the terms, Novartis paid $150 million upfront to Monte Rosa and could pay up to $","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GLUE"],"gpt_icon":0},{"id":"2479517164","title":"Sector Update: Health Care Stocks Rise Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2479517164","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479517164?lang=en_us&edition=fundamental","pubTime":"2024-10-29 03:59","pubTimestamp":1730145586,"startTime":"0","endTime":"0","summary":"Health care stocks edged up late Monday afternoon, with the NYSE Health Care Index adding 0.3% and the Health Care Select Sector SPDR Fund  up 0.2%.The iShares Biotechnology ETF  gained 0.9%.In corporate news, PROCEPT BioRobotics  shares surged past 31% after the company released Q3 results that were above market expectations and raised its revenue outlook for 2024.Monte Rosa Therapeutics  shares soared 98%. The company said Monday that it signed a global development and commercialization license agreement with Novartis  for VAV1-directed molecular glue degraders, including MRT-6160. Novartis shares rose 1.7%.Vera Therapeutics  shares jumped past 15% after the company disclosed long-term efficacy and favorable safety data from its phase 2b trial of kidney disease treatment candidate atacicept.Royal Philips  shares tumbled past 16%. The company cut its full-year comparable sales growth outlook amid a substantial drop in demand in China, while Q3 earnings were little changed.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4532","BK4585","BK4007","IE00BFTCPJ56.SGD","LU0211331839.USD","IE0009355771.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","BK4578","BK4539","BK4082","NVS","XLV","LU2324357040.USD","IE00BJJMRZ35.SGD","VERA","IBB","IE00B2B36J28.USD","BK4588","PRCT","BK4139","IE0002141913.USD","GLUE","BK4581","PHG"],"gpt_icon":1},{"id":"2479145312","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2479145312","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479145312?lang=en_us&edition=fundamental","pubTime":"2024-10-29 02:37","pubTimestamp":1730140627,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics  said Monday that it entered into a global development and commercialization license agreement with Novartis  for VAV1-directed molecular glue degraders, including MRT-6160.Shares of Monte Rosa soared 140% as intraday trading volume catapulted to over 83.7 million from a daily average of more than 349,000.Autonomix Medical  said Monday three patients responded to its radio frequency pain management with femoral access in an ongoing clinical trial evaluating its potential to manage pain in pancreatic cancer patients without the use of opioids.Shares surged 71% as intraday trading volume climbed to more than 17.7 million, versus a daily average of over 20,000.Porch Group  said Monday the Texas Department of Insurance approved its application to form and license a new insurance reciprocal exchange.Shares jumped nearly 80%, with intraday trading volume at over 14.5 million compared with a daily average of more than 846,000.Price: 11.86, Change: +6.97, Percent Change","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00B4R5TH58.HKD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","BK4532","BK4139","BK4122","AMIX","IE00BFTCPJ56.SGD","PRCH","BK4578","GLUE","IE0009355771.USD","BK4539","BK4007","BK4023","BK4585","BK4588","LU0211331839.USD","IE00BJJMRZ35.SGD","NVS","BK4082"],"gpt_icon":0},{"id":"2479643453","title":"Monte Rosa Therapeutics More Than Doubles on Novartis Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2479643453","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479643453?lang=en_us&edition=fundamental","pubTime":"2024-10-29 02:31","pubTimestamp":1730140260,"startTime":"0","endTime":"0","summary":"Shares of Monte Rosa Therapeutics more than doubled and touched a 52-week high after the biotechnology company reported a global exclusive development and commercialization license agreement with Novartis.Monte Rosa stock was up 130%, to $11.25, on Monday, with an intraday high of $12.15, and is up about 103% this year.Terms include a $150 million up-front payment from Novartis. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones.Novartis will obtain exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1-directed molecular glue degraders.MRT-6160 is currently in a continuing Phase 1 healthy volunteer study for immune-mediated conditions.TD Cowen maintained its \"buy\" rating for Monte Rosa. It said the licensing agreement provides validation for the MRT-6160 program and said it believes the economics of the agreement are favorable.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","GLUE","BK4139"],"gpt_icon":0},{"id":"2479493414","title":"Monte Rosa: Novartis Deal Bolsters MGD Platform With Flush Of Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2479493414","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479493414?lang=en_us&edition=fundamental","pubTime":"2024-10-29 02:27","pubTimestamp":1730140057,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics, Inc. secured a $150 million upfront partnership with Novartis to develop MRT-6160 for immune-mediated conditions, with a potential $2.1 billion in milestone payments.Initial d","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160717412/image_2160717412.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160717412/image_2160717412.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4730160-monte-rosa-novartis-deal-bolsters-mgd-platform-with-flush-of-cash","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","GLUE","BK4539"],"gpt_icon":0},{"id":"2479493458","title":"Monte Rosa Stock Doubles — Up 127% — On A Massive Deal With Novartis","url":"https://stock-news.laohu8.com/highlight/detail?id=2479493458","media":"Blockhead","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479493458?lang=en_us&edition=fundamental","pubTime":"2024-10-29 02:10","pubTimestamp":1730139016,"startTime":"0","endTime":"0","summary":"Monte Rosa Therapeutics shares doubled Monday on a deal with Novartis to develop treatments for immune system conditions.","market":"fut","thumbnail":"https://www.investors.com/wp-content/uploads/2019/09/stock-drug-research-01-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2019/09/stock-drug-research-01-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/monte-rosa-therapeutics-novartis-molecular-glue-degraders-deal/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["IE00BJJMRZ35.SGD","BK4532","BK4539","GLUE","IE0002141913.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","LU0211331839.USD","BK4588","IE00BJT1NW94.SGD","BK4139","NVS","BK4578","BK4585","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.monterosatx.com","stockEarnings":[{"period":"1week","weight":0.0969},{"period":"1month","weight":0.7433},{"period":"3month","weight":0.3412},{"period":"6month","weight":1.0409},{"period":"1year","weight":1.849},{"period":"ytd","weight":0.5027}],"compareEarnings":[{"period":"1week","weight":0.0167},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0594},{"period":"6month","weight":0.1248},{"period":"1year","weight":0.3088},{"period":"ytd","weight":0.2529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.156816},{"month":2,"riseRate":0.666667,"avgChangeRate":0.04993},{"month":3,"riseRate":0.666667,"avgChangeRate":0.124226},{"month":4,"riseRate":0,"avgChangeRate":-0.295044},{"month":5,"riseRate":0.333333,"avgChangeRate":0.036693},{"month":6,"riseRate":0.333333,"avgChangeRate":0.028435},{"month":7,"riseRate":0.75,"avgChangeRate":0.0647},{"month":8,"riseRate":0.5,"avgChangeRate":0.131017},{"month":9,"riseRate":0.25,"avgChangeRate":-0.16729},{"month":10,"riseRate":0.75,"avgChangeRate":0.123042},{"month":11,"riseRate":0,"avgChangeRate":-0.085202},{"month":12,"riseRate":0.666667,"avgChangeRate":0.257702}],"exchange":"NASDAQ","name":"Monte Rosa Therapeutics","nameEN":"Monte Rosa Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Monte Rosa Therapeutics,GLUE,Monte Rosa Therapeutics股票,Monte Rosa Therapeutics股票老虎,Monte Rosa Therapeutics股票老虎国际,Monte Rosa Therapeutics行情,Monte Rosa Therapeutics股票行情,Monte Rosa Therapeutics股价,Monte Rosa Therapeutics股市,Monte Rosa Therapeutics股票价格,Monte Rosa Therapeutics股票交易,Monte Rosa Therapeutics股票购买,Monte Rosa Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Monte Rosa Therapeutics(GLUE),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Monte Rosa Therapeutics(GLUE) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction